HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

What Is the Minimum Number of Examined Lymph Nodes After Neoadjuvant Therapy in Rectal Cancer?

AbstractBACKGROUND:
To date, no guidelines have standardized the number of examined lymph nodes (eLNs) after neoadjuvant treatment. This study investigated the minimum number of eLNs required for patients with rectal cancer (RC) who received neoadjuvant treatment.
MATERIAL AND METHODS:
This study was based on data from the Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database. We included 2173 patients with RC who received neoadjuvant therapy. Restricted cubic spline was used to analyze the association between eLNs and lymph node metastasis (LNM).
RESULTS:
The number of eLNs was an independent predictive factor for the presence of LNM (odds ratio 1.033; 95% confidence interval 1.020-1.046; P < 0.001). When the number of eLN ≤ 16, 10 and 11 eLNs had the highest rates of positive LNM. Analysis of the restricted cubic spline method found that when number of eLNs was < 10, the LNM rate increased rapidly, but this increase was not so obviously when there were > 10 eLNs.
CONCLUSIONS:
Among RC patients who receive neoadjuvant therapy, the minimum number of eLNs may be 10 to ensure pathological quality.
AuthorsPeng Gao, Yongxi Song, Yuchong Yang, Shan Zhao, Yu Sun, Jingxu Sun, Xiaowan Chen, Zhenning Wang
JournalJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract (J Gastrointest Surg) Vol. 22 Issue 6 Pg. 1068-1076 (06 2018) ISSN: 1873-4626 [Electronic] United States
PMID29468556 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Topics
  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Lymph Node Excision
  • Lymph Nodes (pathology)
  • Lymphatic Metastasis
  • Male
  • Medicare
  • Middle Aged
  • Neoadjuvant Therapy
  • Neoplasm Staging
  • Rectal Neoplasms (pathology, therapy)
  • SEER Program
  • United States

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: